DRGT Announces Results of Phase I Study Expanding Clinical Utility of the Drug Sirolimus Utilizing the Company’s Novel Super-API Technology Platform

MSIDA, Malta, Oct. 05 (Korea Bizwire) — DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA. Sirolimus, as developed by Pfizer and approved by the FDA, initially failed to achieve sufficient therapeutic effect in [...]